Surgical therapy of exocrine pancreatic carcinoma - Results at an academic teaching hospital and evaluation of prognostic factors

Hepato-Gastroenterology

Volumn 58, Issue 106, 2011, Pages 593-598

  Broese, Maximilian ^a   Hoy, Ludwig ^b   Jaehne, Joachim ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Henriettenstiftung   (Germany)

Author keywords

Median survival; Pancreatic carcinoma; Prognostic factors; Surgery

Indexed keywords

FLUOROURACIL; FOLINATE CALCIUM; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLASSICAL WHIPPLE RESECTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; MORTALITY; PANCREAS CARCINOMA; PANCREAS RESECTION; PANCREATIC LEFT RESECTION; PRIORITY JOURNAL; PROGNOSIS; PYLORUS PRESERVING WHIPPLE RESECTION; SURVIVAL RATE; TEACHING HOSPITAL;

EID: 79958086138     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Reissfelder C, Koch M, Buchler MW, Weitz J: [Pancreatic carcinoma]. Chirurg 2007; 78:1059-1071; quiz 1072.
2. Lowenfels AB, Maisonneuve P: Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 2004; 34:238-244.
3. Friess H, Kleeff J, Fischer L, Muller M, Buchler MW: [Surgical standard therapy for cancer of the pancreas]. Chirurg 2003; 74:183-190.
4. Hopt UT: [Treatment of carcinoma of the pancreatic head]. Zentralbl Chir 2006; 131:115-120.
5. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004; 91:586-594.
6. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M: Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003; 27:324-329. (Pubitemid 36920145)
7. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, Welch HG, Wennberg DE: Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346:1128-1137. (Pubitemid 34984604)
8. Siess M, Siewert JR: [Patient safety in view of specialization, minimum quantity and regionalization]. Dtsch Med Wochenschr 2005; 130:503-507.
9. Keck T, Makowiec F, Adam U, Hopt UT: [Does hospital volume have influence on the results of pancreatic surgery?]. Zentralbl Chir 2007; 132:26-31.
10. Herfarth C: [Pancreatic carcinoma-overcome technically but not oncologically]. Chirurg 2003; 74:163-164.
11. Beger HG, Rau B, Gansauge F, Poch B, Link KH: Treatment of pancreatic cancer: challenge of the facts. World J Surg 2003; 27:1075-1084. (Pubitemid 37259985)
12. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200-1210. (Pubitemid 38339364)
13. Wilkowski R, Thoma M, Schauer R, Wagner A, Heinemann V: Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg 2004; 28:1011-1018. (Pubitemid 40109886)
14. Allendorf JD, Lauerman M, Bill A, DiGiorgi M, Goetz N, Vakiani E, Remotti H, Schrope B, Sherman W, Hall M, Fine RL, Chabot JA: Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival. J Gastrointest Surg 2008; 12:91-100.
15. Adler G, Seufferlein T, Bischoff SC, Brambs HJ, Feuerbach S, Grabenbauer G, Hahn S, Heinemann V, Hohenberger W, Langrehr JM, Lutz MP, Micke O, Neuhaus H, Neuhaus P, Oettle H, Schlag PM, Schmid R, Schmiegel W, Schlottmann K, Werner J, Wiedenmann B, Kopp I: [S3-Guidelines "Exocrine pancreatic cancer" 2007]. Z Gastroenterol 2007; 45:487-523.
16. Brennan MF, Kattan MW, Klimstra D, Conlon K: Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 2004; 240:293-298. (Pubitemid 38963021)
17. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4:567-579.
18. Klempnauer J, Ridder GJ, Bektas H, Pichlmayr R: [Multivariate analysis of prognostic factors after resection of ductal pancreatic carcinomas]. Langenbecks Arch Chir 1995; 380:133-138.
19. Riall TS, Cameron JL, Lillemoe KD, Campbell KA, Sauter PK, Coleman J, Abrams RA, Laheru D, Hruban RH, Yeo CJ: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma-part 3: update on 5-year survival. J Gastrointest Surg 2005; 9:1191-1204; discussion 1204-1196.
20. Seiler CA, Wagner M, Bachmann T, Redaelli CA, Schmied B, Uhl W, Friess H, Buchler MW: Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. Br J Surg 2005; 92:547-556. (Pubitemid 40685648)
21. Karpoff HM, Klimstra DS, Brennan MF, Conlon KC: Results of total pancreatectomy for adenocarcinoma of the pancreas. Arch Surg 2001; 136:44-47; discussion 48.
22. Fischer L, Friess H, Z'Graggen K, Uhl W, Buchler MW: [Operative management in the treatment of pancreatic cancer]. Zentralbl Chir 2003; 128:390-395.
23. Muller MW, Friess H, Kleeff J, Dahmen R, Wagner M, Hinz U, Breisch-Girbig D, Ceyhan GO, Buchler MW: Is there still a role for total pancreatectomy? Ann Surg 2007; 246:966-974; discussion 974-965.
24. Kulu Y, Schmied BM, Werner J, Muselli P, Buchler MW, Schmidt J: Total pancreatectomy for pancreatic cancer: indications and operative technique. HPB (Oxford) 2009; 11:469-475.
25. Makowiec F, Post S, Saeger HD, Senninger N, Becker H, Betzler M, Buhr HJ, Hopt UT: Current practice patterns in pancreatic surgery: results of a multi-institutional analysis of seven large surgical departments in Germany with 1454 pancreatic head resections, 1999 to 2004 (German Advanced Surgical Treatment study group). J Gastrointest Surg 2005; 9:1080-1086; discussion 1086-1087.
26. Bachellier P, Nakano H, Oussoultzoglou PD, Weber JC, Boudjema K, Wolf PD, Jaeck D: Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile? Am J Surg 2001; 182:120-129.
27. Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, van Gulik TM, Obertop H, Gouma DJ: Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004; 40:549-558.
28. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama 2007; 297:267-277. (Pubitemid 46143304)
29. Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8:123-132. (Pubitemid 32199408)
30. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24:3946-3952.
31. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L, Lacaine F, Buckels J, Deakin M, Adab FA, Sutton R, Imrie C, Ihse I, Tihanyi T, Olah A, Pedrazzoli S, Spooner D, Kerr DJ, Friess H, Buchler MW: Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234:758-768.
32. Han SS, Jang JY, Kim SW, Kim WH, Lee KU, Park YH: Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 2006; 32:271-275.
33. Shimizu Y, Yasui K, Matsueda K, Yanagisawa A, Yamao K: Small carcinoma of the pancreas is curable: new computed tomography finding, pathological study and postoperative results from a single institute. J Gastroenterol Hepatol 2005; 20:1591-1594. (Pubitemid 43961116)
34. Scheunemann P, Stoecklein NH, Rehders A, Bidde M, Metz S, Peiper M, Eisenberger C, Schulte Am Esch J, Knoefel WT, Hosch SB: Frequency and prognostic significance of occult tumor cells in lymph nodes in patients with adenocarcinoma of the papilla of Vater. HPB (Oxford) 2007; 9:135-139. (Pubitemid 46672388)
35. Roder JD, Thorban S, Pantel K, Siewert JR: Micrometastases in bone marrow: prognostic indicators for pancreatic cancer. World J Surg 1999; 23:888-891. (Pubitemid 29398468)
36. Mann O, Strate T, Schneider C, Yekebas EF, Izbicki JR: Surgery for advanced and metastatic pancreatic cancer-current state and perspectives. Anticancer Res 2006;26:681-686. (Pubitemid 43206034)
37. Picozzi VJ, Kozarek RA, Traverse LW: Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003; 185:476-480. (Pubitemid 36513960)
38. Beger HG, Poch B, Schwarz M, Gansauge F: [Pancreatic cancer. The relative importance of neoadjuvant therapy]. Chirurg 2003; 74:202-207.